Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Lorvotuzumab mertansine is an ADC targeting CD56 with a maytansinoid payload
doi: 10.1073/pnas.1903798116 95 TohJWTWilsonRB
Our team of experienced injectors ensures a safe and effective treatment experience
This approach prevents overstimulation and allows your tissues to reset and respond more favorably during active treatment phases
Journal of Endocrinology, 236(2), 63-78
David R
US$ 24.01
US$ 29.37
US$ 29.49
